Related Experiment Video
Updated: Jun 13, 2025
Development of a Benchtop Model for Evaluating the Compatibility of Wound Dressing Materials with Negative Pressure Wound Therapy Systems
Published on: May 2, 2025
Design, Synthesis, and Biological Evaluation of New PDE4 Inhibitors for the Treatment of Pressure Ulcers
Xudong Qian1,2, Gang Li2, Yan Geng2
1School of Pharmacy and Food Engineering, Wuyi University, Jiangmen 529020, China.
Abstract:
Pressure ulcers (PU) are an inflammatory skin disease that causes localized tissue ulceration and ischemic necrosis. In this work, a new series of PDE4 inhibitors were designed and synthesized for the treatment of PU. Potential compound G1 exhibited an IC50 value of 29 nM against PDE4D and inhibited the production of TNF-α (IC50 = 13.32 μM) and NO (IC50 = 2.32 μM). In a rat PU model, G1 exhibited the capability to reduce the expression levels of inflammatory markers in skin tissue, diminish the thickness of the epidermal layer, decrease the number of dermal inflammatory cells, and significantly enhance the quantity of fibroblasts, which effectively expedited the wound healing process. Furthermore, G1 exhibited analgesic effects by increasing the pain threshold under hot plate tests, which may find varying possible applications in the clinic. These results imply that the new PDE4 inhibitor G1 is a promising therapeutic option for PU.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...